Trial · NCT02340520
Enhancement of Corticosteroid Efficacy in COPD
NCT02340520, Phase 3, Completed, UConn Health; results first posted 2018-06-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Enhancement of Corticosteroid Efficacy in COPD. Trials, record NCT02340520. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02340520
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Enhancement of Corticosteroid Efficacy in COPD
- NCT number
- NCT02340520
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 13 participants, actual
- Lead sponsor
- UConn Health
- Conditions
- COPD
- Interventions
- Theophylline, Roflumilast
- First posted
- 2015-01-16
- Last updated
- 2018-06-19
- Results first posted
- 2018-06-19
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Bronchodilation | Baseline, Week 1 and 2 | Change in FEV1 L and FVC L |
| Secondary | Change in HDAC2 Levels | Baseline, Week 1 and 2 | circulating Histone Deacetylase2 levels measured in blood sample |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Bronchodilation | Baseline, Week 1 and 2 | liters | MEAN | |
| SECONDARY | Change in HDAC2 Levels | Baseline, Week 1 and 2 | µM/µg | MEAN |
Source ClinicalTrials.gov
Results by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Bronchodilation | Theophylline and Roflumilast | baseline FEV1 | 1.18 | Standard Deviation 0.51 | liters |
| Bronchodilation | Theophylline and Roflumilast | baseline FVC | 2.72 | Standard Deviation 0.78 | liters |
| Bronchodilation | Theophylline and Roflumilast | week 1 FEV1 | 1.22 | Standard Deviation 0.51 | liters |
| Bronchodilation | Theophylline and Roflumilast | week 1 FVC | 2.90 | Standard Deviation 0.82 | liters |
| Bronchodilation | Theophylline and Roflumilast | post steroid week 1 FEV1 | 1.18 | Standard Deviation 0.51 | liters |
| Bronchodilation | Theophylline and Roflumilast | post steroid week 1 FVC | 2.72 | Standard Deviation 0.68 | liters |
| Bronchodilation | Theophylline and Roflumilast | week 2 FEV1 | 1.25 | Standard Deviation 0.58 | liters |
| Bronchodilation | Theophylline and Roflumilast | week 2 FVC | 2.79 | Standard Deviation 0.71 | liters |
| Bronchodilation | Theophylline and Roflumilast | week 2 post steroid FEV1 | 1.18 | Standard Deviation 0.51 | liters |
| Bronchodilation | Theophylline and Roflumilast | week 2 post steroid FVC | 2.81 | Standard Deviation 0.61 | liters |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Theophylline and Roflumilast | 11 | |
| Overall Study | COMPLETED | Theophylline and Roflumilast | 8 | |
| Overall Study | NOT COMPLETED | Theophylline and Roflumilast | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Theophylline and Roflumilast | 0 | 11 |
| Total, other adverse events | Theophylline and Roflumilast | 0 | 11 |
| Total, serious adverse events | Theophylline and Roflumilast | 0 | 11 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02340520
GET https://conductscience.org/api/trials/v1/NCT02340520/registered